<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01082263</url>
  </required_header>
  <id_info>
    <org_study_id>D1050269</org_study_id>
    <nct_id>NCT01082263</nct_id>
  </id_info>
  <brief_title>Midazolam Drug-Drug Interaction Study With Lurasidone HCl</brief_title>
  <sponsors>
    <lead_sponsor>
      <agency>Sunovion</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Sunovion</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      A Phase I, Drug-Drug Interaction Study between Midazolam and Lurasidone HCl.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      lurasidone 120 mg, midazolam 5 mg

      To compare the single-dose pharmacokinetic profile of midazolam 5 mg when administered alone
      vs. when administered with a single-dose of lurasidone 120 mg.

      To compare the single dose pharmacokinetic profile of midazolam 5 mg when administered alone
      vs. when administered after steady state dosing with lurasidone 120 mg.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>October 2008</start_date>
  <completion_date type="Actual">November 2008</completion_date>
  <primary_completion_date type="Actual">November 2008</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">24</enrollment>
  <condition>Schizophrenia Patients</condition>
  <arm_group>
    <arm_group_label>Midazolam/Lurasidone</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Schizophrenia patient</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Lurasidone HCl</intervention_name>
    <description>Day1: 5 mg midazolam (2.5 mL of the 2 mg/mL syrup) Day6: 120 mg lurasidone (three 40 mg tablets) + 5 mg midazolam (2.5 mL of the 2 mg/mL syrup) Day 7-12: 120 mg lurasidone (three 40 mg tablets) 120 mg lurasidone (three 40 mg tablets) on Day 13 + 5 mg midazolam (2.5 mL of the 2 mg/mL syrup)</description>
    <arm_group_label>Midazolam/Lurasidone</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Diagnosis of schizophrenia, schizoaffective disorder, or schizophreniform disorders

          2. Females who participate in this study:

             are unable to have children -OR- are willing to remain abstinent from Day -5 to 90
             days after discharge; -OR- are willing to use an effective method of double-barrier
             birth control from Day -5 to 90 days after discharge.

          3. Males must be willing to remain sexually abstinent or use an effective method of birth
             control from Day -5 to 90 days after discharge.

          4. Able and agree to remain off of prior antipsychotic medication for the duration of the
             study.

        Exclusion Criteria:

          1. Known presence or history of renal or hepatic insufficiency.

          2. A history or presence of abnormal electrocardiogram (ECG5. Known history or presence
             of clinically significant intolerance to antipsychotic medications.

          3. Significant orthostatic hypotension (i.e. a drop in systolic blood pressure of 30 mmHg
             or more and/or drop in diastolic blood pressure of 20 mmHg or more on standing).

          4. Presence or history (within the last year) of a medical or surgical condition (e.g.
             gastrointestinal disease) that might interfere with the absorption, metabolism, or
             excretion of orally administered lurasidone.

          5. Participated in another clinical trial or receiving an investigational product within
             30 days prior to drug administration.

          6. Use of concomitant medications that prolong the QT/QTc interval within 14 days prior
             to Day -5 to follow-up including but not limited to those listed in Appendix 19.5.

          7. Received depot neuroleptics unless the last injection was at least 1 treatment cycle
             before Day -5.

          8. Difficulty fasting or consuming the FDA high fat meals.

          9. At risk with midazolam dosing with respiratory disease or impaired gag reflex, in the
             opinion of the investigator.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Marina Bussel, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>CCT/Parexel</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>CCT/Parexel</name>
      <address>
        <city>Culver City</city>
        <state>California</state>
        <zip>90232</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>September 2011</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>March 5, 2010</study_first_submitted>
  <study_first_submitted_qc>March 5, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 8, 2010</study_first_posted>
  <last_update_submitted>September 6, 2011</last_update_submitted>
  <last_update_submitted_qc>September 6, 2011</last_update_submitted_qc>
  <last_update_posted type="Estimate">September 8, 2011</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>DDI study between Midazolam and Lurasidone HCl</keyword>
  <keyword>Male and Female</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Schizophrenia</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Midazolam</mesh_term>
    <mesh_term>Lurasidone Hydrochloride</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

